Century Therapeutics, Inc. Common Stock
IPSCCentury Therapeutics, Inc. (IPSC) is a biotechnology company focused on developing allogeneic cell therapies for solid tumors and hematologic cancers. Leveraging its proprietary platform, Century aims to create off-the-shelf, living medicines using induced pluripotent stem cell (iPSC) technology to address unmet medical needs in cancer treatment.
Company News
Century Therapeutics announced the appointments of Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, bringing extensive experience in biotechnology, corporate development, and life science investment.
Century Therapeutics has developed an innovative iPSC-derived beta islet therapy (CNTY-813) for Type 1 Diabetes, engineered with Allo-Evasionâ„¢ 5.0 technology to potentially provide durable glucose control without chronic immunosuppression. Preclinical data shows promising results in glucose normalization and immune protection.
Century Therapeutics will present at the H.C. Wainwright 27th Annual Global Investment Conference in September 2025, with an on-demand webcast available and investor meetings scheduled.
The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.
Century Therapeutics has entered into an agreement for an investigator-initiated Phase 1/2 trial of its CNTY-101 cell therapy in patients with B-cell mediated autoimmune diseases. The trial will be led by renowned experts and aims to evaluate the safety, efficacy, and translational data of CNTY-101 in various autoimmune conditions.
